Black Diamond Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: BDTX · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1701541
| Field | Detail |
|---|---|
| Company | Black Diamond Therapeutics, Inc. (BDTX) |
| Form Type | 8-K |
| Filed Date | Jun 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: BDTX
TL;DR
BDTX filed an 8-K for a shareholder vote - details TBD.
AI Summary
Black Diamond Therapeutics, Inc. filed an 8-K on June 12, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain details about the specific proposals voted upon or their outcomes.
Why It Matters
This filing indicates that Black Diamond Therapeutics held a shareholder vote, which could pertain to significant corporate actions or governance changes.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new financial information or significant operational changes.
Key Players & Entities
- Black Diamond Therapeutics, Inc. (company) — Registrant
- June 12, 2025 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of Black Diamond Therapeutics' security holders?
The filing does not specify the exact proposals voted on, only that matters were submitted for a vote.
When was the report filed with the SEC?
The report was filed on June 12, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Black Diamond Therapeutics, Inc.
What is the company's principal executive office address?
The principal executive offices are located at One Main Street, 14th Floor, Cambridge, MA 02142.
Does this filing disclose any financial results or material agreements?
No, this 8-K filing is specifically for reporting matters submitted to a vote of security holders and does not disclose financial results or material agreements.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding Black Diamond Therapeutics, Inc. (BDTX).